Arnab Basu/uabmedicine.org
Jan 2, 2025, 19:20
Longitudinal ctDNA monitoring as a predictive biomarker for metastatic RCC – International Urology Cancer Summit
International Urology Cancer Summit shared an article by Arnab Basu on LinkedIn:
“Advancing Precision Oncology in Metastatic RCC.
New findings highlight the potential of longitudinal ctDNA monitoring as a predictive biomarker for treatment response and progression-free survival in metastatic renal cell carcinoma (RCC).
This study demonstrates high concordance between ctDNA dynamics and clinical outcomes, paving the way for more personalized approaches to therapy and surveillance.
Discover how these insights could impact the future of RCC management.
Read the full study here.”
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.
Authors: Arnab Basu, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 2, 2025, 19:13
Jan 2, 2025, 19:11
Jan 2, 2025, 16:57
Jan 2, 2025, 16:50
Jan 2, 2025, 16:50
Jan 2, 2025, 16:48